Valneva Austria GMBH
$1.6M 1 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Datascope Corp.
Datascope Corp. reported $1,599,239.49 across General Payments, Research, and Ownership to 14 physicians and teaching hospitals across 14 transactions.
- $1.6M Above-median payer
- All-tracks total
- 14 Below-median volume
- Transactions
- 14 Below-median reach
- Recipients
- +$1.6M
- General Payments vs PY2023
Datascope Corp. reported $1,599,239.49 across all CMS Open Payments tracks (General + Research + Ownership) to 14 physicians and teaching hospitals in Program Year 2024 - ranking #509 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,599,239.49, averaging $114.2K per recipient.
Datascope Corp.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
25/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer datascope-corp Datascope Corp.
$1.6M · #509/1,925 · 0.0% industry · PY2024
- TOT $1.6M
- RANK #509
- SHARE 0.0%
- TXN 14
- RCP 14
- CAT 2
- GEN $1.6M
- ΔGEN +$1.6M
- TOP1 50.4%
- PY 2024
Volume peers
Nearest volume peer: Valneva Austria GMBH ($1.6M)
Datascope Corp. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Datascope Corp.'s CMS-reported General Payments increased by $1.6M (+381653.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: DATASCOPE CORP.PY2023: DATASCOPE CORP.PY2024: Datascope Corp.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $418.92
- PY2024
- $1,599,239.49
What the Data Shows for Datascope Corp.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Datascope Corp. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Acquisitions" at $1.6M, accounting for 100.0% of this company's General Payments and 10 transactions.
General Payment Breakdown by Type
Datascope Corp. made 2 types of general payments. "Acquisitions" is the largest category at $1.6M, 100.0% of General Payments.
How Datascope Corp. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Acquisitions | $1.6M | 10 | 100.0% |
| Food and Beverage | $255.49 | 4 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,598,984.00 (100.0%) of $1,599,239.49 in this company's General Payments records across 7 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Datascope Corp.
The five named recipients with the highest reported General Payments from this company
- 1
Cleveland Clinic Hospital
$805,384.00 across 2 reported transactions
- 2
Harish Lecamwasam
$436,448.00 across 2 reported transactions
- 3
Peter Pronovost
$151,576.00 across 2 reported transactions
- 4
Thomas Mark
$131,208.00 across 2 reported transactions
- 5
Michael Smith
$74,368.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Datascope Corp.'s spend rank (#509 of 1,925, top 26% by spend) and concentration rank (#511 of 1,838, top 28% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Winter Innovations, Inc. : $4.7K total payments, HHI 3468
- ONY Biotech Inc. : $39.6K total payments, HHI 3464
- Cardinal Health 110 LLC : $92.3K total payments, HHI 3463
- Agile Therapeutics, Inc. : $131.2K total payments, HHI 3462
- Novabone Products : $19.0K total payments, HHI 3461
- NovoSource, LLC : $22.9K total payments, HHI 3460
- Datascope Corp. (this company) : $1.6M total payments, HHI 3460
- Bristol Myers Squibb Company : $1.0M total payments, HHI 3447
- Collegium Pharmaceutical, Inc. : $1.5M total payments, HHI 3442
- Granata Bio Corporation : $5.5K total payments, HHI 3437
- American Rheumatology Network, LLC : $2.8M total payments, HHI 3431
- Biocircuit Technologies Inc : $69.8K total payments, HHI 3424
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Datascope Corp.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Datascope Corp..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Datascope Corp..
Showing 6 of 1,924 companies with CMS-reported payment data.
restor3d, inc.
$1.6M 1,071 recipients
Compare payment profiles
Ethicon US, LLC
$1.6M 15,448 recipients
Compare payment profiles
Grifols Shared Services North America, Inc.
$1.6M 138 recipients
Compare payment profiles
Avita Medical Americas, Llc
$1.6M 2,776 recipients
Compare payment profiles
Rigel Pharmaceuticals, Inc.
$1.6M 5,780 recipients
Compare payment profiles
Put this to use
Datascope Corp. ranks #509 of 1,925 by all-tracks total payments, led by "Acquisitions".
- See where Datascope Corp. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Acquisitions" spend across every manufacturer, not just Datascope Corp.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.